Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 23; no. 2; pp. 238 - 246
• Main Authors: Mullins, E. S., Stasyshyn, O., Alvarez‐Román, M. T., Osman, D., Liesner, R., Engl, W., Sharkhawy, M., Abbuehl, B. E.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2017
• Subjects: Antibodies; Bleeding; Child; Child, Preschool; Children; Coagulation factors; extended half‐life FVIII; Factor VIII - therapeutic use; Factor VIII deficiency; Female; Hemophilia; Hemophilia A - drug therapy; Hemophilia A - pathology; Humans; Immunogenicity; Male; Pharmacokinetics; Polyethylene glycol; Prophylaxis; Prospective Studies; Quality of Life; Side effects; children; prophylaxis; extended half-life FVIII

Introduction Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half‐life (T1/2) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy. Aims To determine immunogenicity, phar...